received a Form 483 from the USFDA after completion of GMP and PAI review at its Srikakulam manufacturing plant. The regulatory document highlights five specific concerns identified during the inspection process. The company will need to provide written responses addressing each concern within the regulatory timeframe to maintain compliance with US pharmaceutical standards. Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations.